Drugs / L-NAME
L-NAME
Trials 7
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06633198 | May 2025 → Dec 2028 expected | — | William Hughes | Active not recruiting | No outcome recorded |
| Phase 0 | NCT06499844 | Aug 2024 → Aug 2025 overdue | — | University of Iowa | Recruiting | No outcome recorded |
| Phase 0 | NCT06159608 | Dec 2023 → Dec 2026 expected | — | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 12 trials | ||||||
| Phase 1 | NCT06911372 | Aug 2025 → Apr 2027 expected | gestational diabetes | Anna Stanhewicz, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT03684213 | Oct 2018 → May 2024 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00835224 | May 2010 → Jun 2013 | orthostatic hypotension, spinal cord injury | US Department of Veterans Affairs | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT00603720 | Sep 2005 → Jun 2008 | cardiovascular disorder | Washington University School of Medicine | Completed | No outcome recorded |
| Comparator or background therapy4 trials | ||||||
| Phase 1 | NCT03679780 Background | Oct 2018 → Jul 2023 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 1 | NCT03680573 Background | Jan → May 2018 | cardiovascular disorder | The University of Texas at Arlington | Completed | No outcome recorded |
| Phase 2 | NCT06424756 Background | Jul 2024 → Mar 2030 expected | — | University of Georgia | Recruiting | No outcome recorded |
| — | NCT01290198 Comparator | Feb 2011 → Apr 2012 | — | University Hospital, Grenoble | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | L-NAME | “acetylcholine, and acetylcholine + L-NAME (Nitric oxide synthase inhibitor) are locally and acutely delivered to the cutaneous microvasculature to assess endothelium- and...” NCT06499844 ↗7“A total of three microdialysis sites will be perfused with ringer's solution, L-NAME, or ketorolac (one drug per site).” NCT06911372 ↗ |
| Known as | L-NMMA | “Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)” NCT01290198 ↗ |
| Known as | NG-nitro-L-arginine methyl ester | “Local heating + L-NAME (NG-nitro-L-arginine methyl ester; nitric oxide synthase inhibitor)” NCT06159608 ↗ |
| Known as | nitro-L-arginine methyl ester | “A nitric oxide synthase inhibitor (NOSi), nitro-L-arginine methyl ester (L-NAME), has been shown by our group to "normalize" blood pressure in persons with tetraplegia (32).” NCT00835224 ↗ |
| Action | Inhibit | “nitric oxide synthase inhibitor” NCT00603720 ↗ |
| Route | Other | “infusion” NCT00603720 ↗ |